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Abstract There are large numbers of different intracel-
lular signaling pathways regulated by Tyrosine kinases
(Trk) receptors. Trk receptors, especially TrkB, are also
frequently overexpressed in a variety of human malignant
tumors. In this study, we have computationally designed
small peptide-based inhibitors of TrkB and investigated
their effects on the proliferation and apoptosis of two
ovarian cancer cell lines. Molecular docking of TrkB with
its ligand and antagonist, BDNF and Cyclotraxin B
respectively, was carried out using HADDOCK program.
A peptide library was constructed based on the critical
residues involved in the TrkB binding site. After docking
and optimization, two selected peptides were purchased
and their effects on the viability and apoptosis of the cells
were evaluated by performing MTT (3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide) test and flow
cytometry assay. Subsequently, the levels of expression
and phosphorylation statues of TrkB and its two down-
stream genes including MAPK3 and eIF4E were assessed
with western blot. We found that designed peptides
effectively reduced TrkB, MAPK3 and eIF4E phosphory-
lation, reduced cell viability and induced apoptosis in the
treated cells when compared to untreated cells. In conclu-
sion, the BDNF/TrkB signaling is shown to be attenuated
substantially in the presence of peptide inhibitors sug-
gesting a strong inhibitory potential of the designed pep-
tides for Trk family.
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Introduction
The Tyrosine kinases (Trk) receptor family is one of the
best-known class of transmembrane receptors that is nec-
essary for development and survival of the mammalian
nervous system. There are three most common types of Trk
receptors including TrkA, TrkB, and TrkC which have
different binding affinity to certain types of neurotrophins
(Nakagawara 2001). Comparisons of their function indicate
that TrkB and TrkC are the receptors for BDNF, NT4 and
NT3 respectively, while TrkA is activated by nerve growth
factor (NGF). These tyrosine kinase receptors are highly
related to different intracellular signaling pathways regu-
lating proliferation, cell survival, axonal and dendritic
growth, synapse formation, cytoskeleton remodeling and
membrane trafficking (Huang and Reichardt 2003). It has
been widely demonstrated that Trk receptors activate both
MAPKs and Akt, leading ultimately to further downstream
signaling pathways for cell proliferation and development
(Jang et al. 2007). However, many studies have reported
that skewed population of neurons expresses TrkB, which
suggests that this receptor plays a critical role in the reg-
ulation of neuronal development in vivo (Li et al. 2012).
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Furthermore, other important studies underline the role of
TrkB in the invasion ability of cancer cells. Ectopic
expression of TrkB and its ligand, BDNF, has been shown
to be associated with aggressive tumor behavior and poor
prognosis in cancer patients (Okamura et al. 2012). TrkB is
also overexpressed by some tumors of the ovarian cancer
(Yu et al. 2008), lung cancer (Go¨tz and Sendtner 2014),
colorectal cancer (Dawson et al. 2014), neuroblastoma,
prostate adenocarcinoma, Wilm’s tumors, pancreatic ade-
nocarcinoma and myeloma, and is linked to an increased in
anti-cancer drug resistance and tumor invasion (Thiele
et al. 2009). Previously, Fujikawa et al. (2012) demon-
strated that high TrkB expression is accompanied by
epithelial-to-mesenchymal transition (EMT) in colorectal
cancer resulting in enhanced tumor metastasis (Fujikawa
et al. 2012). Accordingly, TrkB receptor can be considered
as a promising target in attempts to inhibit tumor invasion
and metastasis. Based on the Trk receptors, some strategies
have been proposed for drug discovery to overcome
chemotherapy resistance in Trk-associated cancers, but
these efforts have not yet been very successful (Maina
2014). Recently, Cazorla et al. designed a potent anti-TrkB
inhibitor by using peptidomimetic approach. This small
peptide, Cyclotraxin B, could sufficiently alter the con-
formation of TrkB receptor resulting in the inhibition of
BDNF/TrkB signaling and its downstream targets (Cazorla
et al. 2010). This study demonstrates that TrkB targeting
using peptide-based inhibitors can considerably modulate
BDNF/TrkB pathway resulting in a decreased function of
proliferation-related genes in TrkB overexpressed cancer
cells.
Small peptide-based inhibitors are very interesting
candidates for cancer therapy because of their unique
physicochemical properties (Wu et al. 2014). TrkB is a
well-characterized protein which synthesized as single-pass
transmembrane and has been recently considered as a
potentially suitable receptor for designing new small pep-
tide antagonists (Cazorla et al. 2010). Although inhibition
of TrkB receptor may effectively reduce cancer invasion
during cancer progression, most studies have been focused
on the TrkB activation in the neural disorders through
small-molecule agonists (Jiang et al. 2013; Zeng et al.
2013).
In this study, we designed several BDNF-derived small
peptides using molecular docking studies and evaluated
their effects on the proliferation and apoptosis of TrkB
overexpressed ovarian cancer cells. These peptides were
designed based on the binding site of BDNF located at the
variable region III of BDNF. Among five top peptides, two
peptides were chosen for experimental analysis. These
peptides, PEP1 and PEP2, could bind to and significantly
inhibit TrkB activity as well as its two downstream genes,
MAPK3 and eIF4E, in the ovarian cancer cell lines.
Materials and Methods
In Silico Design of Peptide Inhibitor Using
Molecular Docking
A library of the TrkB small peptides was built corre-
sponding to the region III of the BDNF with sequence of
N0-Thr56-Lys57-Cys58-Asn59-Pro60-Met61-Gly62-Tyr63-Thr64-
Lys65-Glu66-C’ using HADDOCK software (De Vries et al.
2007). Preparing of the 3D structures was the starting point
for the modeling studies. The crystal structure of both TrkB
(PDB code: 1WWB) and BDNF (PDB code: 1B8M) proteins
obtained from PDB database (www.rcsb.org). Prior to dock-
ing, the 3D structures of proteins were visualized by PyMOL
program and unwanted molecules were removed from the
PDB files (http://pymol.sourceforge.net). After the study of
the interaction of TrkB with BDNF and Cyclotraxin B, the
key residues involved in the interaction were determined and
provided as input to the Rosetta software for designing new
peptides (Rohl et al. 2004). We used the Backrub for flexible
peptide-backbone modeling and sequence tolerance protocol
for designing the stable peptides. Finally, the models with
high scores were selected using the R software (2012). During
the backrub protocol many mutations were generated that
need to be sorted based on energy score. In order to identify
the most stable sequences, we used R software for sorting
generated ensembles. The 3D structure of selected peptides
was modeled using PEP-FOLD modeling program (Maupetit
et al. 2009). Molecular docking studies were carried out using
HADDOCK software and schematic representation of docked
complexes were generated using the LIGPLOT program
(Wallace et al. 1995).The energy value of docked peptides
was evaluated and eventually, two peptides with lower energy
than others were selected and synthesized by TAG Copen-
hagen (Copenhagen, Denmark).
Molecular Dynamics Simulation
Molecular dynamics (MD) simulation was carried out
using GROMACS (version 4.5) software package (Pronk
et al. 2013). The 3D structures of peptide-TrkB complexes
were solvated in a solvation box with 10 A˚ distance
between the edges of the box and the protein fragments. In
order to neutralize the system, Na? and Cl- ions were
added into the system. The equilibrated systems were
subjected to 10 ns MD simulation in the isothermal–iso-
baric (NPT) ensemble using the leap-frog algorithm with
an integration time step of 0.002 ps.
Cells and Cell Culture
The SK-OV-3 and OV-CAR-3 cell lines were purchased
from American Type Culture Collection (Manassas, VA).
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The cells were maintained in RPMI 1640 supplemented
with 10 % FBS and 10 lg/ml penicillin. Both cell lines
were seeded in their respective growth media and cultured
in a humidified atmosphere of 5 % CO2 and 95 % air at
37 C.
Cell Growth Assay
The cytotoxic effect of inhibitory peptides on the SK-OV-3
and OV-CAR-3 cancer cell lines was measured using MTT
dye reduction assay. The cells (7 9 104 cells/100 ll
media) were seeded in 96-well plates and were grown for
24 h. Then, cells were incubated with different concen-
trations of the inhibitory peptides (50,200,350 and 500 nM)
for 24, 48 and 72 h. The plates were then incubated with
100 ll of 0.5 mg/ml MTT solution for 4 h at 37 C. The
formed formazan crystals were dissolved by the addition of
100 ll/well DMSO and the absorbance was measured at
570 nm by a 96-well micro plate ELISA reader. Data were
presented as relative percent viability with respect to
untreated and Cyclotraxin B-treated cells. The IC50was
calculated from mean ± SD values.
Apoptosis Analysis
After an overnight incubation, cells were treated with
200 nM control vehicle (Cyclotraxin B) and various con-
centrations (350 and 450 nM) of inhibitory designed pep-
tides for 24 and 48 h. After treatment, cells were stained
with FITC-Annexin V using FITC-Annexin V Detection
kit (Biolegend) followed by flow cytometry. Subsequently,
samples were washed twice with PBS, resuspended in
Annexin-V binding buffer, stained with PI (50 mg/ml) and
kept in the dark for 15 min at 20–25 C. Staining was
measured on a FACScan and percentages of apoptotic cells
were determined using FACSDiva software (BD
Biosciences).
Analysis of TrkB Downstream Signaling Pathways
It has been reported that TrkB is overexpressed more
highly in OV-CAR-3 than SK-OV-3 cells (Yu et al. 2008),
therefore we decided to evaluate peptides effect on the
TrkB signaling pathway in OV-CAR-3 cell line. OV-CAR-
3 cells were grown, treated with 350 nM PEP1, PEP2 and
Cyclotraxin B for 48 h and lysed in Passive Lysis Buffer.
Lysates were centrifuged at 130009g for 10 min at
4 C.Theproteins in the lysate were fractionated on 10 %
SDS-PAGE gel, transferred onto PVDF membrane,
washed, and blocked in TBS with 3 % BSA. Immunode-
tection was carried out using specific primary antibodies:
TrkB, phospho-TrkB, MAPK3, phospho-MAPK3, eIF4E,
phospho-eIF4E (1/1000), and b-actin (1/20,000). The HRP-
conjugated secondary antibodies were used at 1:2500
dilutions. All specific primary and secondary antibodies
were purchased from GenScript (Piscataway, NJ) and Cell
signaling Inc respectively. Untreated cells were taken as
negative control and b-actin was used for loading control.
The blots were processed with the ECL Plus Western
Blotting detection kit (Pierce Biotechnology, Rockford, IL,
USA) and the signal detected using an LAS-3000 image
analyzer (Fuji Photo Film Co., Tokyo, Japan). Quantifica-
tion of Western blots was performed using ImageJ software
(Rasband 2012). The statistical analyses were performed
with SPSS 15.0 software (SPSSInc, Chicago, Illinois) using
Student’s t tests toanalyze statistical significance.
Statistical Analysis
All experiments were done in triplicate, statistical analysis
was performed by using one-way ANOVA and Tukey’s
post hoc tests (a = 0.05).
Result
Peptide Library Construction
A peptide library of random amino acid sequences was
constructed based on genetic algorithm. After generating
the peptide library using backrub and sequence tolerance
protocols, the five most stable peptides were selected based
on the energy scores in the R package and subjected to
HADDOCK docking program (data not shown). The
molecular weight, isoelectric point, instability and other
properties of selected peptides were predicted using
MolProbility and ProtParam web tools (Table 1).
Study of Molecular Docking of Designed Peptides
with TrkB
Initially, 3D structure of selected peptides was predicted
using PEP-FOLD modeling software followed by energy
minimization (Fig. 1). Automated docking of peptides with
TrkB performed using the standard HADDOCK protocol
and the energy value of each peptide calculated and listed
in Table 2. After docking with TrkB, PEP2 had the lowest
energy value among all six analyzed peptides.
The residues of five selected peptides involved in polar
and non-polar interactions with TrkB were illustrated using
LIGPLOT and tabulated in Table 3. Comparative analysis
of HADDOCK result indicated that the designed PEP1
(TGLDSDGLYQN) and PEP2 (NTDLLNSNDNG) had the
highest affinity for TrkB among five selected peptides.
Therefore, these two peptides were selected for experi-
mental analyses. Molecular docking indicated that PEP1,
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PEP2 and Cyclotraxin B had 11, 17 and 14 hydrogen bonds
with TrkB respectively. The proposed positioning of PEP1
and PEP2 on TrkB are shown in Fig. 2. Further details of
these interactions obtained from LIGPLOT package can be
found in the Supplementary Data. The result of molecular
dynamics simulation indicated that both PEP1-TrkB and
PEP2-TrkB complexes are stabilized after almost 4 ns
simulations. The RMSD plot of PEP2-TrkB was even more
acceptable than PEP1-TrkB and Cyclotraxin B-TrkB plots
(Fig. 3). The two best peptides were purchased from TAG
Copenhagen (Copenhagen, Denmark).
Cytotoxic Effect of Designed Peptides on Ovarian
Cancer Cell Lines
For assessment of cytotoxic effect of selected peptides, two
ovarian cancer cell lines including ov-car-3 and sk-ov-3
were treated with selected inhibitory peptides. The 50 %
inhibitory concentration (IC50) of PEP1 and PEP2 were
calculated by performing MTT assay (Table 4). The IC50
of PEP2 was lower than Cyclotraxin B indicating higher
inhibitory potential of PEP2 against TrkB receptor.
Fig. 1 Predicted structures of five selected peptides and Cyclotraxin B using PEP-FOLD tool. a PEP1, b PEP2, c PEP3, d PEP4, e PEP5,
f Cyclotraxin B
Table 2 Docking energy values of selected peptides with TrkB using
HADDOCK
Protein Peptide name Peptide sequence Energy (kcal/mol)
TrkB PEP1 TGLDSDGLYQN -36.8
PEP2 NTDLLNSNDNG -47.9
PEP3 QYQNNQATLDQ -20.4
PEP4 SSTQDTRQNTS -12.5
PEP5 DEKFKKQYFYL -7.1
Cyclotraxin B CNPMGYTKEGC -35.8
Table 1 Predicted properties of five selected peptides using Molprobility and Protparam servers
Peptide name Peptide sequence MW TPI No. NAA No. PAA Chemical formula GRAVY
PEP1 TGLDSDGLYQN 1182.2 3.56 2 0 C49H75N13O21 -0.909
PEP2 NTDLLNSNDNG 1176.1 3.56 2 0 C45H73N15O22 -1.391
PEP3 QYQNNQATLDQ 1322.3 3.80 1 0 C54H83N17O22 -1.900
PEP4 SSTQDTRQNTS 1224.2 5.55 1 1 C45H77N17O23 -2.091
PEP5 DEKFKKQYFYL 1508.7 8.38 2 3 C74H105N15O19 -1.400
Cyclotraxin B CNPMGYTKEGC 1271.4 7.85 1 2 C53H86N14O18S2 -1.373
MW molecular weight, TPI theoretical pI, No. NAA number of negative amino acids, No. PAA number of positive amino acids, GRAVY grand
average of hydropathicity
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Fig. 2 Positioning of a PEP1,
b PEP2 on the TrkB (Cyan) and
hydrogen bonds of PEP1 (c) and
PEP2 (d) with TrkB. The
peptide inhibitors are shown in
the red color. Schematic
representation of hydrogen
bonds between peptides and
TrkB are shown in black dotted
lines. For simplicity, any non-
bonded contacts of TrkB with
peptides have been omitted.
TrkB residues involved in
hydrogen bonding with peptides
are indicated in green color
(Color figure online)
Table 3 Residues of designed peptides interacting with TrkB as predicted by LIGPLOT analysis
Receptor/
inhibitor
Polar interaction forming AAs Non-bonded contacts forming AAs
TrkB Lys333, Thr337, Lys312, Lys364, Leu324, Cys331, Lys328,
Asp349, Tyr329
His335, Thr332, Ile334, Pro313, Val307, Ala314, Leu315,
Gln316, Trp317, Asn325, Glu326, Gln347, Ile330
PEP1 Leu3, Asp4, Asp6, Asn11, Tyr9, Thr1 Gly2, Leu8, Gln10, Gly7
TrkB Ser297, His299, Asn350, Asp349, Asp298, Gln347, Lys333,
Ser327, Thr332, Pro313, Lys312, Leu315
Glu326, Ala314, Val307, Tyr342, Ile334, Cys331, Tyr329,
Lys328, Ile330, His300
PEP2 Asn1, Thr2, Asp3, Leu5, Asn6, Asn8, Asn10, Gly11, Asp9 Ser7, Leu4
TrkB His335, Lys333, Asp349, Lys328, Gln347, Cys331, Glu326,
Leu315, Lys312, His339, Gly309
His300, Thr337, Thr340, Tyr342, Val307, Pro313,Ala363,
Ala314, Ile334, Thr332, Ser327, Ile330, Tyr329
PEP3 Gln11, Asp10, Thr8, Gln6, Asn5, Gln3, Tyr2, Gln1 Leu9, Asn4, Ala7
TrkB Ala314, Ile362, Asn325, Ser327, Ile330, Glu326, Lys328,
Leu315, Lys312
Pro313, Lys364, Phe305,Tyr34, Gly344, Ile334, Lys333,
Thr332, Cys331, Ile323, Gln316, Ala363
PEP4 Leu11, Gln7, Lys5, Asp1, Lys3 Phe4, Glu2, Phe9, Tyr10
TrkB Asp349, Gln347, His300, His343, Ile334, Cys331, Lys333,
Pro313, Glu326, Leu315, Leu324, Ala314, Gln316
Lys364, Trp317, Asn325, Lys312, Lys328, Thr3, Ser327,
Gly344, Thr332, Phe305, Leu348
PEP5 Ser2, Ser1, Asp5, Gln4, Thr6, Gln8, Arg7, Ser11 Asn9, Thr10, Thr3
TrkB Thr332, Ile334, Lys312, Gly344, Val307, Tyr342, Pro313,
Leu315, Trp317, Leu324, Asn325, Glu326
Lys333, His343, Phe305, Thr306, Ala314, Gln316, Leu346,
Ile323, Cys331
Cyclotraxin B Asn2, Cys1, Met4, Tyr6, Thr7, Cys11 Glu9, Lys8, Pro3, Gly5, Gly10
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However, after 24 h treatment of the cells, the IC50 of
PEP1 was clearly higher than Cyclotraxin B. Treatment of
two ovarian cancer cell lines with inhibitory designed
peptides reduced the cell viability significantly (A P value
\0.05 was considered significant). Figure 4 summarizes
the effect of PEP1 and PEP2 on ov-car-3 and sk-ov-3 cell
viability with range 50–500 nM of peptide concentrations
after 24, 48 and 72 h treatment.
Apoptosis Evaluation in the Presence of Designed
Inhibitory Peptides
We evaluated the effect of PEP1 and PEP2 on the apoptosis
of ov-car-3 and sk-ov-3 cell lines. After treatment of cells
with concentration of 350 and 450 nM designed peptides
for 24 and 48 h, we observed slight elevation in the amount
of apoptotic cells. Approximately in both 24 and 48 h after
the treatment with concentration of 350 and 450 nM pep-
tides, the apoptotic cells were obviously increased. Further
details are shown in Table 5. The highest effect of peptides
on the induction of apoptosis were observed in the ov-car-3
cell line compared with sk-ov-3 cell line, especially after
24 h treatment with PEP1 (31.59 and 32.21 % apoptotic
cells at concentration of 350 and 450 nM respectively).
These results confirm that the designed inhibitory PEP1
Fig. 3 The RMSD plot of a PEP1-TrkB, b PEP2-TrkB and c Cyclotraxin B-TrkB complexes simulation. The complexes were subjected to a
10 ns MD simulation with an integration time step of 0.002 ps
Table 4 The IC50 of tested inhibitory peptides
Cell line Peptide name IC50 (nM)
24 h 48 h 72 h
Ov-car-3 PEP1 340.92 199.5 199.21
PEP2 199.52 198 197.3
Cyclotraxin B 200 200 200
Sk-ov-3 PEP1 351.02 199.2 199.4
PEP2 199.45 197.2 198
Cyclotraxin B 200 200 200
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and PEP2 are capable of inducing apoptosis in the ovarian
cancer cells.
Analysis of TrkB Downstream Signaling Pathways
The main importance of BDNF/TrkB signaling is that this
signaling can regulate the function of some proliferation-
related proteins such as MAPKs and eIF4E through directly
phosphorylation of these proteins. Western blotting result
demonstrated that phosphorylation of TrkB, MAPK3 and
eIF4E proteins declined in the treated cells when compared
to control cells (Fig. 5). However, the total level of these
proteins in the treated cells did not reduce significantly. The
inhibition effect of PEP1 and PEP2 on the phosphorylation
of aforementioned proteins, especially on the TrkB, were
considerably higher than Cyclotraxin B. All three peptides
(PEP1, PEP2 and Cyclotraxin B) reduced TrkB phospho-
rylation significantly. In addition, PEP2 also caused a sig-
nificant reduction in eIF4E phosphorylation.
Discussion
In contrast to larger molecules, small peptide-based drugs
would represent more appropriate treatment in cancer
therapy because of their smaller size, excellent tissue
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Fig. 4 The effects of PEP1 and
PEP2 on the ov-car-3 and sk-ov-
3 cell viability. The viability of
two ovarian cancer cell lines
reduced at different
concentrations (50–500 nM) of
designed peptides after 24, 48
and 72 h treatment. a and b ov-
car-3 cell line, c and d sk-ov-3
cell line. Control neg: untreated
cells, Control pos: Cyclotraxin
B-treated cells (Color
figure online)
Table 5 Apoptosis percentage
of treated cells with different
concentrations of PEP1, PEP2
and Cyclotraxin B
Cell line Peptide name Peptide concentration (nM) Apoptosis percentage (%)
24 h 48 h
Ov-car-3 PEP1 350 31.59 17.9
450 32.21 24.99
PEP2 350 23.18 20.79
450 25.33 28.39
Cyclotraxin B 200 19.41 20.85
Negative control 2.82 2.82
Sk-ov-3 PEP1 350 18.07 20.11
450 22.18 25.14
PEP2 350 14.67 23.98
450 24.22 23.53
Cyclotraxin B 200 20.56 16.47
Negative control 2.32 2.32
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penetration and easy synthesis process. There are several
small peptides, also known as cell-penetrating peptides,
that unlike other biotherapeutic agents can efficiently
translocated through the plasma membrane. These peptides
are widely considered as one of the most promising tools
for delivering numerous types of drugs (such as small-
molecule pharmaceuticals, therapeutic proteins, and anti-
sense oligonucleotides) into target cells (Stewart et al.
2008). One of the most important challenges in peptide-
based drug design is to find a promising therapeutic target
1 2 3 4 43
21
1 2 3 4
TrkB
phospho-TrkB
MAPK3
phospho-MAPK3
β-actin β-actin
β-actin
phosphor-eIF4E
eIF4E
* * *
A B
C
*
Fig. 5 Western blot analysis of total and phosphorylated level of
TrkB and its downstream genes. a (Up anti-TrkB antibody, down anti-
phosphoTrkB antibody), b (up anti-MAPK3 antibody, down anti-
phosphoMAPK3 antibody), c (up anti-eIF4E antibody, down anti-
phosphoeIF4E antibody). Lane 1 PEP2, lane 2 PEP1, lane 3
Cyclotraxin B, lane 4 untreated cells. b-actin expression levels in
the sample were used as the loading control. Blots were quantified and
shown above each panel. PEP2 reduced phosphorylation of TrkB and
eIF4E significantly (P value\0.05) (Color figure online)
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associated with cancer progression. It has been shown that
BDNF/TrkB signaling is involved in the pathogenesis of
different cancers mainly in ovarian cancer (Au et al. 2009)
multiple myeloma (Hu et al. 2007) and colon cancer (Yu
et al. 2010). Also, overexpression of TrkB has been
reported in several human malignant tumors such as neu-
roblastoma which is likely to play an unfavorable role in
neuroblastoma resistance to chemotherapy-induced apop-
tosis (Jaboin et al. 2002). There are some of the TrkB
inhibitors which effectively inhibit BDNF/TrkB signaling
in cancer cells and subsequently prevent cancer cell inva-
sion (Desmet and Peeper 2006). AZ623, a TrkB inhibitor,
in combination with another chemotherapy drug (topote-
can) at concentration of 0.8 to 7 lM could inhibit TrkB-
mediated signaling in neuroblastoma (Zage et al. 2011).
Cazorla et al. indicated that the concentration of 200 nM
Cyclotraxin B efficiently inhibited TrkB receptor in vivo
(Cazorla et al. 2010). In this study, we considered Cyclo-
traxin B as positive control. We introduced new potentially
small peptide-based inhibitors of TrkB which could
strongly modulate BDNF/TrkB signaling, even at lower
concentrations compared to Cyclotraxin B. The results of
molecular docking studies revealed that PEP2 had a mod-
erately strong Hydrogen-Bond pattern which results in a
tight interaction with TrkB. The Asn1 residue of PEP2, by
making a 6 hydrogen-bonds pattern with Ser297, Asp298,
His299, Asp349 and Asn350 residues of TrkB, plays a very
important role in the interaction of PEP2 with TrkB
(Fig. 6). Generally, asparagine has potential hydrogen
bonding atoms and plays a critical role in many enzymes
functions and also helps protein refolding by interacting,
directly or indirectly, with the hydrophilic groups (Choma
et al. 2000). There are four asparagine residues in the
sequence of PEP2 which may make a better binding
affinity of this peptide to TrkB receptor.
The results of molecular docking revealed that the
Lys333 residue of TrkB plays a key role in the binding of
peptides to the TrkB. The Lys333 residue, in Cyclotraxin
B-TrkB complex, makes a non-bonded contact with TrkB,
while this residue makes two hydrogen bonds with both
PEP1 (with Leu3 and Asp4 residues) and PEP2 (with Leu5
and Asn6 residues). It is now well established that a
combination of Leu with either Asn or Asp residues is
highly effective in inhibiting protein degradation (CARO
et al. 1989). Combination of Leu with Asp and Asn in
PEP1 and PEP2 respectively, may enhance the therapeutic
effectiveness of these peptides by improving their stability.
Characterization of ligand-binding domain of the Trk
family members have demonstrated that the hydrophilic
residues in the Trk family members play a key role in the
binding of ligands to Trk kinases (Ultsch et al. 1999). Sim-
ilarly, the main candidate region of BDNF involved in the
interaction with its receptor is surrounded by charged and
specificity-conferring residues (Robinson et al. 1999). These
studies indicate that the binding of BDNF to TrkB is highly
dependent on polar interactions between hydrophilic resi-
dues. The physicochemical properties of selected peptides
and Cyclotraxin B calculated by Peptide property calcula-
tion tool of Innovagen (http://www.innovagen.se) showed a
remarkable hydrophilicity scale of PEP2 which might
explain better binding capacity of PEP2 than PEP1 and
Cyclotraxin B (data not shown). Furthermore, the IC50
values of PEP2 were lower in 24, 48 and 72 h than Cyclo-
traxin B in the two treated ovarian cancer cell lines. The
lower IC50 values indicate the greater potency of PEP2 in
antagonizing the BDNF/TrkB signaling. Analysis by Wes-
tern blotting indicated that PEP2 could significantly inhibit
the phosphorylation of TrkB and its downstream genes.
TrkB triggers some downstream signaling pathways
associated with cell growth and development. Activation of
MAPKs cascade can be achieved by Trk receptor activation
and the vast majority of evidences have demonstrated that
MAPKs activation could increase cell migration in non-in-
vasive cancer cells (Krueger et al. 2001). There are several
new strategies for design of improved therapeutic approa-
ches based on MAPKs function model in the cell (De Luca
et al. 2012). Recent studies have reported that mTOR sig-
naling pathway acts as a node of convergence down-stream
of BDNF/TrkB (Slipczuk et al. 2009). BDNF/TrkB-induced
increase of mTOR stimulates synthesis of proteins through
regulation of p70S6K and 4E-BP1 (Park et al. 2014). Indeed,
activated mTOR phosphorylates and inactivates 4E-BP1 by
repressing its binding to eIF4E (Troca-Marı´n et al. 2012).
Then, free eIF4E could bind to the eIF4G and eIF4A and
form eIF4F active complex facilitating translation initiation.
In this study, we found that the phosphorylation of MAPK3
and eIF4E declined after treatment of the cells with TrkB
designed inhibitors. Among three evaluated peptides, PEP2
could significantly inhibit the phosphorylation of eIF4E but
there was no significant reduction in the phosphorylation of
Fig. 6 The six hydrogen-bonds pattern of Asn1 residue of PEP2 (red
color) interacted with TrkB. The residues of TrkB involved in the
interaction with Asn1 residue of PEP2 are shown in blue color (Color
figure online)
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MAPK3 after treatment with inhibitory peptides. On the
basis of recent studies, it is reasonable that the inhibition of
TrkB receptor would not be expected to significantly mod-
ulate the function of MAPK signaling pathway. MAPKs are
involved in many biological processes in a wide range of
eukaryotic organisms. MAPK signaling pathway, which
functions as one of the cell hub signaling pathways, is reg-
ulated by many other signaling pathways such as Tumor
necrosis factor (TNF) (Chen et al. 2007), hypoxia (Risbud
et al. 2005) andRAS/RAF (Hatzivassiliou et al. 2010). There
is a large-scale study that introduces a list of 57 different
genes activating MAPK signaling pathway (Matsuda et al.
2003). However, our results are clearly compatible with
previous studies that have found the reduction in phospho-
rylation of TrkB accompanied by reduced downstream genes
phosphorylation (Cazorla et al. 2010).
Up-regulation of TrkB can promote cell proliferation
(Heo et al. 2013) and chemotherapy resistance (Lee et al.
2012) through inhibiting apoptosis. Expectedly, inhibition of
TrkB by designed peptides slightly increased the amount of
apoptosis in the set of cell lines studied here. Since inhibition
of TrkB cannot completely block the anti-apoptotic function
of BDNF (Takeda et al. 2013), we observed only a slight
increase in the apoptotic cell population.
In conclusion, the aim of present study was to demon-
strate that inhibition of TrkB by peptide-based inhibitors
can considerably down-regulate its downstream target
genes including MAPK3 and eIF4E. In fact, the modulating
of these genes may enhance the chemotherapy responses in
cancer cells through regulation of cell death. Therefore, the
TrKB inhibition by means of rational designed peptides
would be useful in control of that pathway.
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